Reaching a Tipping Point for Neurorehabilitation Research: Obstacles and Opportunities in Trial Design, Description, and Pooled Analysis

William M. Savage, Noam Y. Harel

Research output: Contribution to journalArticlepeer-review

Abstract

The record-breaking pace of COVID-19 vaccine development and implementation depended heavily on collaboration among academic, government, and commercial stakeholders, especially through data-sharing and robust multicenter trials. Collaborative efforts have not been as fruitful in fields such as neurorehabilitation, where non-pharmacological interventions play a much larger role. Barriers to translating scientific advancements into clinical practice in neurorehabilitation include pervasively small study sizes, exacerbated by limited funding for non-pharmacological multicenter clinical trials; difficulty standardizing—and adequately describing—non-pharmacological interventions; and a lack of incentives for individual patient-level data-sharing. These barriers prevent reliable meta-analysis of non-pharmacological clinical studies in neurorehabilitation. This point-of-view will highlight these challenges as well as suggest practical steps that may be taken to improve the neurorehabilitation pipeline between evidence and implementation.

Original languageEnglish
Pages (from-to)659-665
Number of pages7
JournalNeurorehabilitation and Neural Repair
Volume36
Issue number10-11
DOIs
StatePublished - Nov 2022

Keywords

  • collaboration
  • data-sharing
  • meta-analysis
  • multicenter clinical trials

Fingerprint

Dive into the research topics of 'Reaching a Tipping Point for Neurorehabilitation Research: Obstacles and Opportunities in Trial Design, Description, and Pooled Analysis'. Together they form a unique fingerprint.

Cite this